New Alzheimer's treatments may help treat major eye disease, UK researchers say.

When the news of remarkable results in a pre-clinical trial of a potential drug for Alzheimer's disease was released in July, the headlines screamed and the share price for Prana Biotechnology went through the roof. Graeme O'Neill probes the details.

Melbourne's Antisense Therapeutics (ASX:ANP) has raised $3.6 million through a private placement to Australian and professional investors to fund the phase IIa trial of its antisense compound ATL1102 for patients with relapsing remitting multiple sclerosis.

Melbourne's Antisense Therapeutics (ASX:ANP) has been granted approval to restart the phase IIa trial of its antisense compound ATL1102 for patients with relapsing remitting multiple sclerosis.

After three years with the Australian Stem Cell Centre (ASCC), Dr Dianna DeVore has resigned as vice-president of clinical cardiac development, and will be returning to California to pursue stem cell collaborative opportunities, effective December 31.

Melbourne's Antisense Therapeutics (ASX:ANP) is planning to restart the phase IIa trial of its lead drug candidate for multiple sclerosis ATL1102 before the end of the year, following recommendations from its advisory board.

Melbourne's Antisense Therapeutics (ASX:ANP) has reported a full-year after-tax loss of AUD$6.2 million, up from $4.6 million from last year, in results described by CEO Mark Diamond as "good news tinged with less than positive news".

Reports that a potential blockbuster drug for multiple sclerosis, Tysabri, could be back on shelves later this year appear to have given a boost to Melbourne company Antisense Therapeutics (ASX:ANP), which is also developing an MS drug.

Results in Brief: Vertex, Varian, Watson, Chiron, Alcon, Eyetech, Elan, NicOx, MorphoSys, Actelion, AstraZeneca, Shire, GSK, Bristol-Myers Squibb, QLT, Millennium, Celgene, Invitrogen, InterMune, Charles River, Ranbaxy, Takeda, Sankyo, Daiichi, Solvay

A preclinical trial of Metabolic Pharmaceuticals' (ASX:MBP) conotoxin peptide painkiller hints that if it makes it to the clinic, it could provide a health bonus for patients suffering chronic neuropathic pain.

Biogen has withdrawn its 2005 earnings forecast as it can no longer count on revenue from its suspended multiple sclerosis drug Tysabri.